RxDoctor Payments Data

Charles Butrick, MD

Urogynecology and Reconstructive Pelvic Surgery · Overland Park, KSNPI 1295737633

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $86,110 of the $96,728 with a category attached, or 89.0%. Axonics, Inc. accounts for 97.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $65,896 and has fallen 100.0% since, to $15 in 2025.

$96,728in general payments, 2019–2025

Across 135 payments — averaging $716.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$94K
  • AbbVie$402
  • Abbott$361
  • Medtronic$334
  • Astellas Pharma US Inc$309
  • Caldera Medical, Inc$273
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$86,11089%
  • Speaking & faculty fees$3,2213%
  • Travel & lodging$2,7043%
  • Food & beverage$4,5975%
  • Gifts$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$101,215
Medicare patients
174
Services billed
4,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron132$79,603
MyrbetriqMirabegron53$29,974
Estradiol115$8,201
Tizanidine Hcl102$2,306
Amitriptyline Hcl74$1,547
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst64$1,024
Clobetasol Propionate66$1,022
Cephalexin63$870
Baclofen31$848
Methenamine Hippurate23$709
Solifenacin Succinate22$650
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$233
Tamsulosin Hcl13$228
Triamcinolone Acetonide64$207
Cyclobenzaprine Hcl12$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$236$79,603132 claims
Astellas Pharma US IncMyrbetriq$309$29,97453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Kansason file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →